Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors

Author: Hang MIN ¹ ; Mengran GUO ¹ ; Yue YE ¹ ; Xiaoshuang XU ¹ ; Hang MIN ² ; Mengran GUO ² ; Yue YE ² ; Xiaoshuang XU ² ; Donghu ZHEN ²
Author Information

1. The First Clinical Medical College of Lanzhou University
2. Department of Endocrinology, The First Hospital of Lanzhou University
Publication Type:Journal Article
Keywords: Immune checkpoint inhibitors (ICIs); Immunotherapy-related adverse events (IRAEs); Thyroid dysfunction (TD)
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(2):223-229
CountryChina
Language:Chinese
Abstract: Thyroid dysfunction (TD) is one of the commonest endocrine immunotherapy-related adverse events (IRAEs) during cancer patients' treatment with immune checkpoint inhibitors (ICIs). In the hope that cooperation between departments will be enhanced to alleviate the side effect of immunotherapy which thyroid dysfunctions can cause, this review is contributed to make more endocrinologists and oncologists acknowledge and master clinical characteristics, diagnostic methods and therapeutic strategies of thyroid IRAEs, by the introduction of its pathogenesis, epidemiological features, diagnosis, treatment and prognosis.